Vandria SA
Developing mitophagy inducers to treat age-related and chronic diseases
Vandria discovers and develops inhibitors of a novel target which results in the induction of mitophagy - the selective removal and replacement of damaged mitochondria - and anti-inflammatory effects. The target has strong genetic links to several human diseases.
In pre-clinical studies, Vandria’s lead candidate, VNA-318, has been consistently shown to acutely improve memory and learning, and to have strong disease-modifying effects in models of neurodegenerative disease such as Alzheimer’s and Parkinson’s Disease. Toxicity studies have demonstrated VNA-318 to have a wide safety window.
Visit website: https://www.vandria.com/
Details last updated 15-Dec-2023
Vandria SA News
$20.6 million fuels Vandria's mission to conquer ageing and chronic diseases
Longevity Technology - 14-Dec-2023
Mitophagy-boosting drug candidate VNA-318 preps for clinical trials
Read more...